Insights on Clinical Trials

  1. Managing Operational Challenges In CAR-T Clinical Trial Logistics 3/18/2026

    Coordinating CAR-T trials means managing tight timelines, cryogenic handling, staffing gaps, and chain-of-identity risks where even small missteps can delay care.

  2. Lessons From Bringing A Novel T Cell Class For Autoimmune Diseases Into The Clinic 3/13/2026

    Tr1X Bio Co-founder and CEO David de Vries explains how moving Type 1 regulatory T Cell (Tr1) therapies into new indications reshapes every facet of first-in-human trial design.

  3. Why AI Matters In Early Phase Clinical Trials 3/11/2026

    AI speeds early‑phase development by streamlining data review, enabling structured queries, accelerating PK/PD work, and revealing biomarker patterns — boosting efficiency with expert oversight.

  4. Unanticipated Roadblocks In Ovarian Cancer Drug Development 3/9/2026

    Enhance your Ovarian cancer trials by enabling community referral pipelines, aligning imaging with biomarker assessments, and selecting sites based on verifiable surgical capacity.

  5. The Bioanalysis CRO Selection Checklist Every Sponsor Should Use Before Signing An MSA 3/9/2026

    Choosing a CRO requires more than proposals. Assess reliability, automation, GLP rigor, scientific engagement, pricing clarity, and capacity to find partners who deliver defensible data on real timelines.

  6. GLP Compliance In A Modern Lab: What Is Actually Required? 3/9/2026

    GLP compliance isn’t binary. Real defensibility depends on rigorous QA, validated electronic systems, and operational maturity — not just a label.

  7. What Sponsors Get Wrong When Selecting A CRO 3/9/2026

    Gene therapy immunogenicity requires platforms, judgment, and regulatory fluency beyond ADA norms. Relying on biologics criteria creates gaps; CGT expertise ensures reliable, interpretable results.

  8. Why CGT Programs Need A Different CRO Mindset 3/9/2026

    Advanced therapies need bioanalysis partners built for complexity, not scale. CGT expertise, specialized platforms, and flexible timelines ensure dosing and safety data traditional CROs can’t support.

  9. Transparent Pricing In Bioanalysis: A Feature, Not A Bonus 3/9/2026

    Unclear CRO pricing leaves small biotechs vulnerable to budget swings. Transparent, itemized costs cut financial risk, sharpen planning, and build trust by setting expectations from the start.

  10. How Smaller Biotechs Are Rethinking CRO Relationships Post-Pandemic 3/9/2026

    Smaller biotechs are rethinking CRO partnerships, valuing speed, scientific access, flexibility, and transparent pricing over scale — driven by pandemic lessons and a sharper focus on operational fit.